Pharma Raw Materials Tofacitinib Citrate For Psoriasis And Hair Growth CAS 540737-29-9
Basic info.
| Product Name | Tofacitinib Citrate |
|
Synonyms |
1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tofacitinib citrate (CP-690550);Tofacitinib citrate;Tasocitinib citrate; |
| CAS NO | 540737-29-9 |
| MF | C16H20N6O.C6H8O7 |
| MW | 504.497 |
| Appearance | White Crystalline Powder |
| Assay | 98%min |
| Storage | room temp |
| Brand | Pharmlab |
| Delivery | EMS, DHL, TNT, FedEx, UPS |
| Delivery time | within 24 hours upon receipt of payment |
| Product Category | Pharmaceutical raw materials and intermediates |
| Usage | Treat rheumatoid arthritis. |
Description
(1).Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company for treating rheumatoid arthritis , for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis ( RA) in adult patients. Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
(2). It can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) . Tofacitinib citrate is approved by the daily dose of 2 times, each time 5mg. Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Tofacitinib citrate treatment showed significant improvement in clinical response and physical function.
(3).In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis. Using Tofacitinib citrate was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma.Tofacitinib citrate product label attaches boxed warning on these security risks . Tofacitinib citrate treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.In order to study Tofacitinib citrate long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Tofacitinib citrate therapy, and accept a integration of another group of patients approved by the treatment as a control.
Applications
(1).Tofacitinib citrate is an oral, small molecule drug used to treat adults with moderate-to-severe, active rheumatoid arthritis who have not responded well to being treated with methotrexate. Methotrexate is a disease-modifying antirheumatic drug (DMARD) used to treat rheumatoid arthritis (RA).
(2).Tofacitinib acts to block the body's production of enzymes called Janus kinases (JAKs). JAKs play a role in joint inflammation in RA, which can cause pain, swelling and stiffness. If left untreated, RA inflammation could lead to joint erosions, and organ and tissue damage. It may be used alone or in combination with methotrexate or other DMARDs.
COA
| Items | Specifications | Results |
| Appearance/Colors | White solid | White solid |
| Loss on drying | ≤5 .0% | 0.30% |
| Water content(KF) | ≤5 .0% | 0.60% |
| Purity( by HPLC) | ≥ 9 9.0% | 99.80% |
| EE(by SFC) | ≥ 9 8.0% | 100.00% |
| Re-test date | 24 months | |
| H-NMR Spectrum | Sample corresponds to that of standard preparation | Conforms to Structure |
| Conclusion | The product tested complies with the specifications | |
Usage of Tofacitinib citrate
| Psoriasis | Tofacitinib is a current investigational drug in psoriasis. Tofacitinib has demonstrated its effectiveness for plaque psoriasis in Phase 3 randomized, controlled trials in comparison to placebo and to etanercept. In particular, a 10 mg twice-daily dose of tofacitinib was shown to be noninferior to etanercept 50 mg subcutaneously twice weekly. |
| Ulcerative colitis | The phase 3 OCTAVE study of Tofacitinib in ulcerative colitis started in 2012 and completed in 2015. |
| Vitiligo | In a June 2015 case report, a 53-year-old woman with vitiligo showed noticeable improvement after taking tofacitinib for five months |
| Atopic dermatitis | The results of using Tofacitinib in 6 patients with recalcitrant atopic dermatitis was published in the September 2015. All saw improvement in their atopic dermatitis without any adverse events |